RetaNord sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.
By proceeding you affirm the statements above are true. Products are not for human or veterinary use and have not been evaluated by the European Medicines Agency or any other regulatory authority.

Modified GLP-1 analogue
Semaglutide is a synthetic GLP-1 receptor agonist — a modified analogue of human GLP-1 with a fatty-acid chain that greatly extends its half-life. It is the single-receptor benchmark against which newer dual- and triple-agonist peptides are compared.
Both kit sizes ship within the EU — free shipping either way.
Plain, unbranded packaging. No product names, no logos — nothing on the outside indicating what is inside. Tracked to a DPD Locker or your address.
Guaranteed delivery. If your order doesn't reach you, we ship it again free — lost, damaged or stolen.
For laboratory and in vitro research use only. Not for human or veterinary use, and not for use in diagnostic procedures.
Semaglutide is a synthetic analogue of the human incretin hormone GLP-1, structurally modified with a C18 fatty-diacid chain that extends its plasma half-life to around a week. It is one of the most-studied peptides in the incretin class and the reference point for single-receptor agonism in metabolic research.
RetaNord supplies Semaglutide as fixed kits of 10 or 30 lyophilized vials, each verified at 99%+ identity purity by independent third-party HPLC (Janoshik), and every kit ships with a lot-specific Certificate of Analysis. Supplied for laboratory and in vitro research use only.
Semaglutide is a GLP-1 receptor agonist — an analogue of the human incretin hormone GLP-1, sharing most of its sequence. Two amino-acid substitutions make it resistant to enzymatic degradation, and a C18 fatty-diacid chain attached through a short linker promotes binding to serum albumin.
That albumin binding is what stretches the plasma half-life to roughly a week, which is why published work uses a once-weekly rather than a daily schedule. It engages a single incretin receptor — the reference point against which the dual- and triple-agonist molecules that followed are measured.
Mechanistic summary drawn from published literature, provided for research context only. Not a therapeutic claim.
Semaglutide was evaluated in the STEP programme of randomised trials in overweight and obesity, and in the SUSTAIN programme in type 2 diabetes. A 2025 randomised trial compared it head-to-head with tirzepatide.
Where it sits in the class: semaglutide targets GLP-1 alone, tirzepatide adds GIP, and retatrutide adds glucagon as a third receptor. Full breakdown in the comparison, with primary sources in the references below.
An educational summary of published literature. It is not a claim about any outcome for any buyer, and RetaNord supplies this compound for laboratory research use only.
Sealed, lyophilized vials. 2–8 °C for routine storage; −20 °C or below for long-term. Room temperature is for transit and handling only — it is not a storage state for a peptide.
Once reconstituted. Keep at 2–8 °C and never freeze — ice crystals cause irreversible damage. Reconstituted with bacteriostatic water (0.9% benzyl alcohol) a vial is commonly used within about 30 days; with plain sterile water, within 24–48 hours.
Keep vials sealed and protected from light, and minimise freeze–thaw cycles of frozen stock — each cycle costs potency.
Work out concentration and draw volume in the reconstitution calculator →
| Category | Incretin receptor agonist |
|---|---|
| Compound class | Synthetic peptide — GLP-1 receptor agonist |
| Presentation | 10 vials per kit · lyophilized |
| Available sizes | 5 · 10 · 15 · 20 mg per vial |
| CAS number | 910463-68-2 |
| Molecular formula | C187H291N45O59 |
| Molecular weight | ≈ 4114 g/mol |
| Physical form | Sterile-filtered, freeze-dried |
| Identity purity | 99%+ (HPLC) |
| Independent testing | Janoshik · third-party HPLC |
| Storage | 2–8°C; −20°C long term |
| Documentation | Lot-specific Certificate of Analysis |
Certificate of Analysis — batch VX551552Independent third-party testing by Janoshik · HPLC purity 99.452% and content verified.View the full report →Selected peer-reviewed literature via PubMed, provided for educational context. A reference does not imply a clinical claim for RetaNord products.
Yes — every kit ships with a lot-specific third-party Certificate of Analysis: independent HPLC purity and content testing by Janoshik, with the batch matching your vials. View the current CoA.
Semaglutide targets one receptor (GLP-1); tirzepatide targets two (GIP + GLP-1); retatrutide targets three (GLP-1 + GIP + glucagon). All are studied in the same incretin research family.
These research compounds are supplied in fixed kits of 10 identical vials — the standard research quantity. One kit (10 vials) is the minimum order to the EU.
Sealed lyophilized vials keep at 2–8 °C, or −20 °C for long-term storage. Once reconstituted, keep refrigerated and never freeze it. See storage & handling for the full detail.
The volume of bacteriostatic water you add sets the concentration — the vial size alone does not. Enter your vial size and diluent volume in the reconstitution calculator to calculate the concentration for your assay.
Semaglutide is the molecule; Ozempic, Wegovy and Rybelsus are brand names of approved medicines that contain it. RetaNord supplies the research compound — not those products, and not for human use.
Every RetaNord kit ships within 24–48 hours, discreetly packaged and tracked. All kits ship within the EU. For laboratory research use only.
Order this kitA person answers every message — the same day, seven days a week.